Table 2.
Baseline patient characteristics in each category
| Treatment – category | GC-A | GC-B | GC-C | GC-D | GCS-A | GCS-B | GCS-C | GCS-D | p |
|---|---|---|---|---|---|---|---|---|---|
| N | 13 | 20 | 36 | 23 | 40 | 21 | 19 | 11 | |
| Age | 68.3±12.6 | 66.5±9.9 | 67.2±8.4 | 64.7±9.4 | 69.2±7.9 | 65.3±10.4 | 64.9±10.0 | 67.0±5.7 | N.S. |
| Gender, n (%) | |||||||||
| Male | 6 (46) | 11 (55) | 20 (56) | 12 (52) | 22 (55) | 12 (57) | 9 (47) | 4 (36) | 0.9584 |
| Female | 7 (54) | 9 (45) | 16 (44) | 11 (48) | 18 (45) | 9 (43) | 10 (53) | 7 (64) | |
| Diagnosis, n (%) | |||||||||
| Unresectable | 9 (69) | 16 (80) | 30 (84) | 19 (83) | 25 (63) | 18 (86) | 16 (84) | 9 (82) | 0.3124 |
| Locally advanced | 2 (15) | 7 (35) | 10 (28) | 4 (17) | 3 (8) | 5 (24) | 4 (21) | 1 (9) | 0.3806 |
| Metastatic | 7 (54) | 9 (45) | 20 (56) | 15 (65) | 22 (55) | 13 (62) | 12 (63) | 8 (73) | |
| Recurrent | 4 (31) | 4 (20) | 6 (16) | 4 (17) | 15 (37) | 3 (14) | 3 (16) | 2 (18) | |
| Primary tumor, n (%) | |||||||||
| Gall bladder | 6 (46) | 4 (20) | 13 (36) | 10 (43) | 13 (33) | 6 (29) | 11 (58) | 4 (36) | 0.4124 |
| Extrahepatic bile duct | 3 (23) | 5 (25) | 8 (22) | 4 (17) | 13 (33) | 4 (19) | 4 (21) | 5 (46) | |
| Intrahepatic bile duct | 4 (31) | 10 (50) | 15 (42) | 8 (35) | 13 (33) | 10 (47) | 3 (16) | 2 (18) | |
| Ampullary | 0 | 1 (5) | 0 | 1 (5) | 1 (1) | 1 (5) | 1 (5) | 0 | |
| Initial tumor size, mm | 46.5±28.4 | 61.2±36.7 | 58.8±34.0 | 65.0±42.9 | 54.2±32.7 | 65.2±39.0 | 55.8±41.2 | 56.5±37.2 | N.S. |
GC, conventional gemcitabine + cisplatin; GCS, biweekly gemcitabine + cisplatin + S-1.
N.S. indicates p > 0.1 among categories.